Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Am J Physiol Lung Cell Mol Physiol. 2020 Dec 1;319(6):L932-L940. doi: 10.1152/ajplung.00295.2020. Epub 2020 Sep 30.
For patients with end-stage lung disease, lung transplantation is a lifesaving therapy. Currently however, the number of patients who require a transplant exceeds the number of donor lungs available. One of the contributing factors to this is the conservative mindset of physicians who are concerned about transplanting marginal lungs due to the potential risk of primary graft dysfunction. Ex vivo lung perfusion (EVLP) technology has allowed for the expansion of donor pool of organs by enabling assessment and reconditioning of these marginal grafts before transplant. Ongoing efforts to optimize the therapeutic potential of EVLP are underway. Researchers have adopted the use of different large and small animal models to generate translational preclinical data. This includes the use of rejected human lungs, pig lungs, and rat lungs. In this review, we summarize some of the key current literature studies relevant to each of the major EVLP model platforms and identify the advantages and disadvantages of each platform. The review aims to guide investigators in choosing an appropriate species model to suit their specific goals of study, and ultimately aid in translation of therapy to meet the growing needs of the patient population.
对于终末期肺病患者,肺移植是一种救生疗法。然而,目前需要移植的患者人数超过了可供移植的供肺数量。造成这种情况的一个原因是医生的保守思维,他们担心由于原发性移植物功能障碍的潜在风险,移植边缘肺会带来风险。体外肺灌注 (EVLP) 技术通过在移植前对这些边缘供体进行评估和再处理,扩大了供体器官库。目前正在努力优化 EVLP 的治疗潜力。研究人员已经采用了不同的大动物和小动物模型来生成转化前临床数据。这包括使用被拒绝的人肺、猪肺和鼠肺。在这篇综述中,我们总结了与每个主要 EVLP 模型平台相关的一些关键现有文献研究,并确定了每个平台的优缺点。综述旨在指导研究人员选择合适的物种模型来满足其特定的研究目标,并最终有助于将治疗方法转化为满足患者群体不断增长的需求。